NovoCure Ltd. NVCR
NASDAQ · United States · Health Technology
$15.92-0.03 (-0.19%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
BAAR, Switzerland, October 01, 2026--Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
BAAR, Switzerland, October 01, 2026--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open.
NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what the market expects those sales to become over time? Over the past 5 years the share price has fallen 86.1%, which puts the current valuation debate squarely on whether the remaining market value still lines up with the revenue base. The business model...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.